ReviewFrontiers in pharmacology2026
Evidence for the use of anti-CD20 therapeutic antibodies in immune thrombotic thrombocytopenic purpura management: a review.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Immune thrombotic thrombocytopenic purpura (iTTP) is an autoimmune thrombotic microangiopathy caused by antibody-mediated deficiency of the plasma metalloprotease ADAMTS13. Therapeutic antibodies that target antibody-producing B-cells via the CD20 surface receptor protein to prevent disease exacerbation and relapse have become part of the standard of care of patients with iTTP. However, clinical trial data regarding the use of anti-CD20 agents is limited to mostly phase II studies; no universally agreed-upon standardized protocol for the use of CD20-targeting antibodies for iTTP regarding choice of agent, dosage, or duration of treatment exists; refractoriness or lack of response to anti-CD20 antibodies can occur; and several agents and biosimilars are now available for the treatment of iTTP patients, which complicates the decision tree for clinicians caring for these patients. In this review, we explore the current landscape of anti-CD20 therapeutics used to treat iTTP, focusing on agents currently available for clinical use. We describe the pharmacokinetic and pharmacodynamic properties of CD20-targeting antibodies; available data regarding dosage and duration of treatment; anti-CD20 antibody therapy refractoriness or lack of response; and the evolving role of anti-CD20 biosimilars. This review will shed light on the state-of-the-art in CD20-targeting antibodies used to treat iTTP patients with an eye toward identifying areas in need of further study to aid in the care of patients with this rare and often devastating disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.